Paolo Tarantino: Some HER2+ tumors melt upon dual anti-HER2 Treatment
Paolo Tarantino shared on X:
“Some HER2+ tumors melt upon dual anti-HER2 Treatment; others require chemo, or don’t respond to anything. Dissecting them, a key challenge with huge clinical impact. Find the latest understanding on anti-HER2 treatment tailoring in our latest article, led by Ada Waks.”
Authors: Adrienne G. Waks, Olga Martínez-Sáez, Paolo Tarantino, Fara Braso-Maristany, Tomás Pascual, Javier Cortés, Sara M. Tolaney and Aleix Prat
Source: Paolo Tarantino/X
More posts featuring Paolo Tarantino on oncodialy.com
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023